Free Newsletter
Minnesota Partnership awards $5.4M for research
The Minnesota Partnership for Biotechnology and Medical Genomics--a collaboration between the University of Minnesota, Mayo Clinic and the state of Minnesota--has awarded $5.4 million in research funds for six projects on cancer, neurological diseases, heart disease, gastrointestinal conditions and nanotechnology. "These six projects reflect some of the best science and scientific minds in Minnesota. All of these projects have a strong likelihood of succeeding and advancing to the bioscience marketplace," explains Eric Wieben, Ph.D., Partnership program director at Mayo Clinic.
The state-backed program takes projects developed jointly by University and Mayo Clinic researchers and provides funds to help them develop intellectual property or attract additional research support. "These six projects reflect some of the best science and scientific minds in Minnesota. All of these projects have a strong likelihood of succeeding and advancing to the bioscience marketplace," explains Eric Wieben, Ph.D., Partnership program director at Mayo Clinic.
- check out nanowerk for more on each award
Related Article:
Minnesota blueprints new complex for biomedical research
Comments
By Anonymous | Posted 2:37pm | March 13, 2009
I have read that 5.4 million in research funds for six projects on cancer, neurological diseases, heart disease, gastrointestinal conditions and nanotechnology. I really think we should consider funding research on regeneration hair cells in the inner ear for hearing. 30 million people in the US alone suffer from different types of hearing loss. As we age no matter what we do we lose our hair cells cause us to lose our hearing. This effects every single person in the world. I really think this is something we should start really focusing one. On a toll hearing loss in population is way higher than any other disease. Don't get me wrong I appreciate the funding that is being provided.
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession
SHARE
WITH: